Nuzenio

Verastem Oncology Doses

Verastem Oncology Doses news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Cancer trials begin Phase 2 enrollment as Verastem signs up to $75M deal - Stock TitanStock Titan · Thu, 06 Aug 2026 20:01:00 GMTVerastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes - Stock TitanStock Titan · Wed, 05 Aug 2026 20:37:40 GMTVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMTVerastem, Inc. doses first patient in Phase 2 TARGET-D 203 trial for KRAS G12D-mutated colorectal cancer - Traders UnionTraders Union · Tue, 28 Jul 2026 07:00:00 GMT

Timeline

Thu, 06 Aug 2026 20:01:00 GMTCancer trials begin Phase 2 enrollment as Verastem signs up to $75M deal - Stock Titan
Wed, 05 Aug 2026 20:37:40 GMTVerastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes - Stock Titan
Tue, 28 Jul 2026 07:00:00 GMTVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer - Yahoo Finance
Tue, 28 Jul 2026 07:00:00 GMTVerastem, Inc. doses first patient in Phase 2 TARGET-D 203 trial for KRAS G12D-mutated colorectal cancer - Traders Union

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Verastem Oncology Doses.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.